Wave Life Sciences (WVE) Competitors

Wave Life Sciences (NASDAQ:WVE) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, community ranking, analyst recommendations, valuation, media sentiment and institutional ownership.

Do analysts prefer WVE or RNA?

Wave Life Sciences currently has a consensus price target of $21.17, indicating a potential upside of 166.58%. Avidity Biosciences has a consensus price target of $66.69, indicating a potential upside of 104.01%. Given Wave Life Sciences' higher possible upside, equities research analysts plainly believe Wave Life Sciences is more favorable than Avidity Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Wave Life Sciences	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	3.00
Avidity Biosciences	0 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals and insiders hold more shares of WVE or RNA?

89.7% of Wave Life Sciences shares are owned by institutional investors. 29.1% of Wave Life Sciences shares are owned by insiders. Comparatively, 3.7% of Avidity Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Which has more risk and volatility, WVE or RNA?

Wave Life Sciences has a beta of -0.93, suggesting that its stock price is 193% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Does the MarketBeat Community prefer WVE or RNA?

Wave Life Sciences received 200 more outperform votes than Avidity Biosciences when rated by MarketBeat users. However, 69.14% of users gave Avidity Biosciences an outperform vote while only 67.90% of users gave Wave Life Sciences an outperform vote.

Company	Underperform	Outperform
Wave Life Sciences	Outperform Votes 368 67.90%	Underperform Votes 174 32.10%
Avidity Biosciences	Outperform Votes 168 69.14%	Underperform Votes 75 30.86%

Is WVE or RNA more profitable?

Wave Life Sciences has a net margin of -66.50% compared to Avidity Biosciences' net margin of -2,772.45%. Avidity Biosciences' return on equity of -27.66% beat Wave Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Wave Life Sciences	-66.50%	-280.57%	-52.90%
Avidity Biosciences	-2,772.45%	-27.66%	-24.56%

Does the media prefer WVE or RNA?

In the previous week, Wave Life Sciences had 7 more articles in the media than Avidity Biosciences. MarketBeat recorded 17 mentions for Wave Life Sciences and 10 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.67 beat Wave Life Sciences' score of 1.00 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Wave Life Sciences	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Avidity Biosciences	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has stronger valuation and earnings, WVE or RNA?

Wave Life Sciences has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Wave Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Wave Life Sciences	$108.30M	11.25	-$57.51M	-$0.79	-10.05
Avidity Biosciences	$10.90M	360.62	-$212.22M	-$2.89	-11.31

Summary

Wave Life Sciences beats Avidity Biosciences on 11 of the 18 factors compared between the two stocks.